1. Home
  2. NBR vs GYRE Comparison

NBR vs GYRE Comparison

Compare NBR & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nabors Industries Ltd.

NBR

Nabors Industries Ltd.

HOLD

Current Price

$68.90

Market Cap

746.4M

Sector

Energy

ML Signal

HOLD

Logo Gyre Therapeutics Inc.

GYRE

Gyre Therapeutics Inc.

HOLD

Current Price

$7.91

Market Cap

755.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NBR
GYRE
Founded
1952
2002
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
746.4M
755.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NBR
GYRE
Price
$68.90
$7.91
Analyst Decision
Hold
Strong Buy
Analyst Count
8
2
Target Price
$54.13
$17.00
AVG Volume (30 Days)
364.8K
84.8K
Earning Date
02-11-2026
03-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
14.43
0.04
Revenue
$3,116,983,000.00
$107,265,000.00
Revenue This Year
$9.76
$11.59
Revenue Next Year
$0.25
$26.31
P/E Ratio
$4.58
$209.75
Revenue Growth
6.52
2.13
52 Week Low
$23.27
$6.11
52 Week High
$70.61
$13.75

Technical Indicators

Market Signals
Indicator
NBR
GYRE
Relative Strength Index (RSI) 68.95 51.65
Support Level $63.23 $7.84
Resistance Level $70.61 $8.28
Average True Range (ATR) 2.72 0.32
MACD 0.04 0.02
Stochastic Oscillator 83.38 43.70

Price Performance

Historical Comparison
NBR
GYRE

About NBR Nabors Industries Ltd.

Nabors Industries Ltd owns and operates land-based drilling rig fleets and is a provider of offshore platform rigs in the United States and international markets. It also provides performance tools, directional drilling services, tubular running services, and technologies. The company has four reportable segments: U.S. Drilling, International Drilling, Drilling Solutions, and Rig Technologies. The key revenue of the company is generated from International Drilling.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Share on Social Networks: